ATE426389T1 - Verfahren zur herstellung und verwendung von theaflavin, theaflavin-3-gallat, theaflavin-3'- gallat und theaflavin 3,3'-digallat und ihrer gemische - Google Patents

Verfahren zur herstellung und verwendung von theaflavin, theaflavin-3-gallat, theaflavin-3'- gallat und theaflavin 3,3'-digallat und ihrer gemische

Info

Publication number: ATE426389T1
Authority: AT; Austria
Prior art keywords: theaflavin; gallate; digallate; mixtures; production
Prior art date: 2001-11-28

Application number

AT02804079T

Other languages

English (en)

Inventor

Jian Zhao

Rui Zhou

Hu Room Chen

Original Assignee

Nashai Biotech Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-28

Filing date

2002-11-27

Publication date

2009-04-15

2002-04-26 Priority claimed from CNB021115125A external-priority patent/CN1156276C/zh

2002-11-27 Application filed by Nashai Biotech Llc filed Critical Nashai Biotech Llc

2009-04-15 Application granted granted Critical

2009-04-15 Publication of ATE426389T1 publication Critical patent/ATE426389T1/de

Links

239000000203 mixture Substances 0.000 title abstract 7
GPLOTACQBREROW-UHFFFAOYSA-N Phlegmanol A-acetat Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC1=2)C=C(O)C(=O)C1=C(O)C(O)=CC=2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 GPLOTACQBREROW-UHFFFAOYSA-N 0.000 title abstract 6
KMJPKUVSXFVQGZ-UHFFFAOYSA-N TF2B Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 KMJPKUVSXFVQGZ-UHFFFAOYSA-N 0.000 title abstract 6
235000014620 theaflavin Nutrition 0.000 title abstract 5
ZEASWHWETFMWCV-UHFFFAOYSA-N 7-O-(2-O-Acetyl-6-O-Methyl-beta-D-glucuronoside)-4',5,7-Trihydroxyflavone Natural products C=1C(O)=C(O)C2=C(O)C(=O)C=C(C3C(CC4=C(O)C=C(O)C=C4O3)OC(=O)C=3C=C(O)C(O)=C(O)C=3)C=C2C=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 ZEASWHWETFMWCV-UHFFFAOYSA-N 0.000 title abstract 3
IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 title abstract 3
UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 title abstract 3
BVMDSEFJGKQBKJ-UHFFFAOYSA-N Theaflavin 3'-gallate Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O BVMDSEFJGKQBKJ-UHFFFAOYSA-N 0.000 title abstract 3
ZEASWHWETFMWCV-ISBUVJFSSA-N Theaflavin 3,3'-digallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C2=CC(=CC(=O)C(O)=C2C(O)=C(O)C=1)[C@@H]1[C@@H](CC2=C(O)C=C(O)C=C2O1)OC(=O)C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 ZEASWHWETFMWCV-ISBUVJFSSA-N 0.000 title abstract 3
IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 title abstract 3
229940026509 theaflavin Drugs 0.000 title abstract 3
IKLDTEFDTLKDRK-UHFFFAOYSA-N theaflavin 3'-gallate Natural products OC1Cc2c(O)cc(O)cc2OC1c3cc4C=C(C=C(O)C(=O)c4c(O)c3O)C5Oc6cc(O)cc(O)c6CC5OC(=O)c7cc(O)c(O)c(O)c7 IKLDTEFDTLKDRK-UHFFFAOYSA-N 0.000 title abstract 3
DZGQZNRJDFZFLV-UHFFFAOYSA-N theaflavin 3,3'-digallate Natural products OC1=CC(=Cc2cc(C3Oc4cc(O)cc(O)c4CC3OC(=O)c5cc(O)c(O)c(O)c5)c(O)c(O)c2C1=O)C6Oc7cc(O)cc(O)c7CC6OC(=O)c8cc(O)c(O)c(O)c8 DZGQZNRJDFZFLV-UHFFFAOYSA-N 0.000 title abstract 3
AATSUYYYTHJRJO-UHFFFAOYSA-N theaflavin 3-gallate Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC(=O)C(O)=C1C(O)=C2O)C=C1C=C2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 AATSUYYYTHJRJO-UHFFFAOYSA-N 0.000 title abstract 3
235000002365 theaflavin-3'-gallate Nutrition 0.000 title abstract 3
235000008230 theaflavin-3,3'-digallate Nutrition 0.000 title abstract 3
235000007900 theaflavin-3-gallate Nutrition 0.000 title abstract 3
AATSUYYYTHJRJO-RZYARBFNSA-N theaflavin-3-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=C(O)C(O)=C2C(=O)C(O)=CC(=CC2=C1)[C@H]1OC2=CC(O)=CC(O)=C2C[C@H]1O)C(=O)C1=CC(O)=C(O)C(O)=C1 AATSUYYYTHJRJO-RZYARBFNSA-N 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 abstract 4
239000008194 pharmaceutical composition Substances 0.000 abstract 3
235000005911 diet Nutrition 0.000 abstract 2
230000037213 diet Effects 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
239000013589 supplement Substances 0.000 abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Neurology (AREA)
Oncology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT02804079T 2001-11-28 2002-11-27 Verfahren zur herstellung und verwendung von theaflavin, theaflavin-3-gallat, theaflavin-3'- gallat und theaflavin 3,3'-digallat und ihrer gemische ATE426389T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US33351501P	2001-11-28	2001-11-28
CNB021115125A CN1156276C (zh)	2002-04-26	2002-04-26	茶黄素的新用途
US41357602P	2002-09-24	2002-09-24

Publications (1)

Publication Number	Publication Date
ATE426389T1 true ATE426389T1 (de)	2009-04-15

Family

ID=27178819

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02804079T ATE426389T1 (de)	2001-11-28	2002-11-27	Verfahren zur herstellung und verwendung von theaflavin, theaflavin-3-gallat, theaflavin-3'- gallat und theaflavin 3,3'-digallat und ihrer gemische

Country Status (10)

Country	Link
EP (1)	EP1460999B1 (de)
JP (1)	JP2005523242A (de)
KR (1)	KR20080052675A (de)
AT (1)	ATE426389T1 (de)
AU (1)	AU2002365415C1 (de)
CA (1)	CA2467664A1 (de)
DE (1)	DE60231747D1 (de)
MX (1)	MXPA04005113A (de)
NZ (2)	NZ533190A (de)
WO (1)	WO2003045328A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005077384A1 (ja) *	2004-02-17	2005-08-25	Suntory Limited	高分子ポリフェノール画分を含有するリパーゼ活性阻害剤、茶エキス、およびその製造方法
JP5242885B2 (ja) *	2004-05-20	2013-07-24	株式会社伊藤園	筋肉内ａｍｐｋ活性化剤
JP5159108B2 (ja) *	2004-07-05	2013-03-06	サントリーホールディングス株式会社	リパーゼ阻害剤
JP4880965B2 (ja) *	2005-10-03	2012-02-22	株式会社ヤクルト本社	抗脂肪性薬剤
CA2650403A1 (en)	2006-04-26	2007-11-08	Ito En, Ltd.	Compositions comprising theaflavins and gallates thereof useful as fat absorption inhibitors
JP5441046B2 (ja) *	2006-05-01	2014-03-12	国立大学法人筑波大学	脂肪肝の予防および／または治療剤
TW201000019A (en) *	2008-03-28	2010-01-01	Shizuoka Prefectural University Corp	Manufacturing method for theaflavins, using raw tea leaves
JP2010095477A (ja) *	2008-10-17	2010-04-30	Ito En Ltd	リパーゼ阻害剤
JP2010095478A (ja) *	2008-10-17	2010-04-30	Ito En Ltd	体脂肪蓄積抑制剤及び飲食品
JP5614674B2 (ja) *	2009-09-18	2014-10-29	万壽美竹元	生活習慣病予防及び改善剤
JP2012072084A (ja) *	2010-09-29	2012-04-12	Kracie Home Products Ltd	エラスターゼ阻害剤並びにそれを含有する化粧品組成物及び医薬品組成物
CN103103227A (zh) *	2013-01-18	2013-05-15	徐州医学院	一种具有α-葡萄糖苷酶抑制作用的茶多酚氧化聚合物的制备工艺
JP6478368B2 (ja) *	2013-12-26	2019-03-06	大塚食品株式会社	テアフラビン類の製造方法、及びテアフラビン類を含む飲料
JP6514684B2 (ja) *	2014-03-27	2019-05-15	焼津水産化学工業株式会社	口腔内細菌増殖抑制剤
WO2015198614A1 (ja) *	2014-06-27	2015-12-30	株式会社Ｎｂｃメッシュテック	テアフラビン類の合成用触媒およびテアフラビン類の合成方法
CN106511362B (zh) *	2015-09-15	2020-11-17	广东省人民医院	一种防治动脉粥样硬化的茶多酚组合物
JP6778506B2 (ja) *	2016-04-21	2020-11-04	焼津水産化学工業株式会社	機能性食品組成物
JP2018138529A (ja) *	2017-02-24	2018-09-06	株式会社ダイセル	テアフラビン類を利用したレプチン分泌促進剤
WO2020218755A1 (ko) *	2019-04-25	2020-10-29	㈜아모레퍼시픽	테아플라빈을 포함하는 지방세포 분화 촉진용 조성물
KR102359446B1 (ko) *	2019-04-25	2022-02-09	(주)아모레퍼시픽	테아플라빈을 포함하는 지방세포 분화 촉진용 조성물
US12582592B2 (en) *	2019-08-01	2026-03-24	Ogawa & Co., Ltd.	Flavor or aroma deterioration inhibitor containing theanaphthoquinone and analogues thereof as active ingredient
CN114533723A (zh) *	2022-01-19	2022-05-27	湖南农业大学	一种调节骨骼肌糖代谢与线粒体生成的膳食营养补充剂及其应用
CN116687910A (zh) *	2022-02-26	2023-09-05	湖南农业大学	可调节雌激素信号通路的茶组合物及其在防治神经退行性疾病中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2975057A (en) *	1958-05-23	1961-03-14	Lipton Inc Thomas J	Process for converting green tea extract
CH570772A5 (de) *	1972-01-31	1975-12-31	Unilever Nv
JPS63214183A (ja) *	1987-03-03	1988-09-06	Mitsui Norin Kk	アンジオテンシン１変換酵素阻害剤
US5318986A (en) *	1989-10-19	1994-06-07	Mitsui Norin Co., Ltd.	Method of inhibiting the activity of α-amylase
JP3018013B2 (ja) *	1989-10-19	2000-03-13	三井農林株式会社	α―アミラーゼ活性阻害剤
CN1035660C (zh) *	1993-01-01	1997-08-20	江西省绿色工业(集团)公司	茶色素及其生产方法
JP4127863B2 (ja) *	1993-03-04	2008-07-30	太陽化学株式会社	腸内環境改善組成物
ES2153939T3 (es) *	1995-09-04	2001-03-16	Unilever Nv	Procedimiento para intensificar el color de un producto alimentario a base de te.
DE19627344A1 (de) *	1996-07-01	1998-01-08	Vitasyn Gmbh Entwicklung & Ver	Therapeutisch wirksame bzw. gesundheitsfördernde Zubereitung aus definierten Polyphenolverbindungen
JPH1132725A (ja) *	1997-07-24	1999-02-09	Mitsui Norin Kk	流動食
JP2000327572A (ja) *	1999-05-18	2000-11-28	Mitsui Norin Co Ltd	スクアレンエポキシダーゼ阻害剤
CN1328092A (zh) *	2000-06-08	2001-12-26	陈虎	一种新的提取茶色素的方法及其在高血脂方面的应用

2002
- 2002-11-27 NZ NZ533190A patent/NZ533190A/en not_active IP Right Cessation
- 2002-11-27 JP JP2003546833A patent/JP2005523242A/ja active Pending
- 2002-11-27 WO PCT/US2002/038177 patent/WO2003045328A2/en not_active Ceased
- 2002-11-27 CA CA002467664A patent/CA2467664A1/en not_active Abandoned
- 2002-11-27 AU AU2002365415A patent/AU2002365415C1/en not_active Expired
- 2002-11-27 NZ NZ569389A patent/NZ569389A/en not_active IP Right Cessation
- 2002-11-27 DE DE60231747T patent/DE60231747D1/de not_active Expired - Lifetime
- 2002-11-27 KR KR1020087009558A patent/KR20080052675A/ko not_active Ceased
- 2002-11-27 AT AT02804079T patent/ATE426389T1/de not_active IP Right Cessation
- 2002-11-27 EP EP02804079A patent/EP1460999B1/de not_active Expired - Lifetime
- 2002-11-27 MX MXPA04005113A patent/MXPA04005113A/es active IP Right Grant

Also Published As

Publication number	Publication date
EP1460999A4 (de)	2005-03-09
NZ533190A (en)	2008-07-31
AU2002365415C1 (en)	2008-12-11
EP1460999A2 (de)	2004-09-29
WO2003045328A3 (en)	2003-10-09
NZ569389A (en)	2010-01-29
WO2003045328A2 (en)	2003-06-05
DE60231747D1 (de)	2009-05-07
EP1460999B1 (de)	2009-03-25
CA2467664A1 (en)	2003-06-05
AU2002365415A1 (en)	2003-06-10
AU2002365415B2 (en)	2008-04-10
MXPA04005113A (es)	2005-04-29
JP2005523242A (ja)	2005-08-04
KR20080052675A (ko)	2008-06-11

Legal Events

Date	Code	Title	Description
2009-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60231747D1 (de)	2009-05-07	Verfahren zur herstellung und verwendung von theaflavin, theaflavin-3-gallat, theaflavin-3'-gallat und theaflavin 3,3'-digallat und ihrer gemische
WO2004112715A3 (en)	2005-04-07	Methods of making and using theaflavin,theaflavin-3-gallate, theaflavin-3’-gallate and theaflavin 3,3’ - digallate and mixtures thereof
BG66103B1 (bg)	2011-04-29	Кондензирани пиролокарбазоли
BG105177A (en)	2001-11-30	Novel substituted pyrazole derivatives
BG103740A (en)	2000-05-31	Phytostyrene composition for the prevention of the alzheimer's disease
IL110031A0 (en)	1994-10-07	Phenyl heterocycles, their manufacture and pharmaceutical compositions containing them
PL348237A1 (en)	2002-05-20	Fused 1,2,4-thiadiazine derivatives, their preparation and use
SG158731A1 (en)	2010-02-26	Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
ES2142570T3 (es)	2000-04-16	Bisesteres de acido alqu(en)ildicarboxilico, su empleo, asi como procedimientos para su obtencion.
WO2004043954A3 (en)	2004-11-18	Trans-9,10-dehydroepothilone c and d, analogs thereof and methos of making the same
ATE471924T1 (de)	2010-07-15	3-alkyl-5,5',6,6',7,7',8,8'-octahydro-2,2'- binaphthole und 3,3'-dialkyl-5,5',6,6',7,7',8,8'- octahydro-2,2'-binaphthole, sowie verfahren zur ihrer herstellung
BG103485A (en)	2000-01-31	Ketobanzamides as calpain inhibitors
WO1998041513A3 (de)	1999-03-11	Substituierte aminosalicylsäureamide mit fungizider wirkung und zwischenprodukte zu ihrer herstellung
WO2000021910A3 (en)	2000-07-06	1,2-disubstituted cyclopropanes
SG149045A1 (en)	2009-01-29	Novel fused pyrrolocarbazoles
WO2005063764A3 (en)	2005-08-25	Fused pyrrolocarbazoles and methods for the preparation thereof
TW200420294A (en)	2004-10-16	Methods of making and using theaflavin, thealflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3, 3'-digallate and mixtures thereof
DE69927602D1 (de)	2005-11-10	Verfahren zur herstellung von vitaminpulvern
AU4080097A (en)	1998-03-19	Piperazino derivatives as neurokinin antagonists
CA2218887A1 (en)	1996-11-07	Piperazino derivatives as neurokinin antagonists
DE69901519D1 (de)	2002-06-27	Verfahren zur Herstellung von 2,2'-bis (Hydroxymethyl)alkansäure
WO2001081298A3 (en)	2002-05-02	Cyclic carboxylic acids as integrin antagonists
ATE339423T1 (de)	2006-10-15	Verfahren zur herstellung von 4'-o-substituierten 4'-demethyl-1 desoxypodophyllotoxinderivaten und geometrischen isomeren davon ,und antikrebspräparat, das diese enthält
ATE299851T1 (de)	2005-08-15	Verfahren zur herstellung von zwischenprodukten
MX337902B (es)	2016-03-22	Metodos para hacer y utilizar teaflavin, teafavlin-3-galato, teaflavin-3'-galato y teaflavin 3,3´-digalato y mezclas de las mismas.